INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 11, 2009, Pages 1329-1340

  Cooper DeHoff, Rhonda M ^a,b   Handberg, Eileen M ^b   Mancia, Giuseppe ^c   Zhou, Qian ^d   Champion, Annette ^d   Legler, Udo F ^e   Pepine, Carl J ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d ABBOTT LABORATORIES   (United States)

^e ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Atenolol; Coronary artery disease; Hydrochlorothiazide; Hypertension; INVEST; New onset diabetes; Trandolapril; Verapamil SR

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANTILIPEMIC AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PARKINSON DISEASE; REVIEW; RISK REDUCTION; WHEEZING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERY DISEASE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDOLES; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VERAPAMIL;

EID: 73349138608     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.102     Document Type: Review

References (53)

1. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), e21-e181 (2009). • Most up-to-date statistics related to heart disease and stroke.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002).
3. Neal B, MacMahon S. The World Health Organization - International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressurelowering treatments. Curr. Hypertens. Rep. 1(4), 346-356 (1999).
4. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366(9496), 1545-1553 (2005).
5. Messerli FH, Bangalore S, Julius S. Risk/ benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117(20), 2706-2715; discussion 2715 (2008).
6. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113(9), 1213-1225 (2006).
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
9. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157(21), 2413-2446 (1997).
10. Pepine CJ, Handberg-Thurmond E, Marks RG et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension. J. Am. Coll. Cardiol. 32(5), 1228-1237 (1998). • Full details describing the rationale and design of the International Verapamil SR-Trandolapril (INVEST) clinical trial.
11. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin. Cardiol. 21(9), 633-641 (1998).
12. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1(2), 113-119 (1992).
13. Cooper-DeHoff R, Handberg E, Heissenberg C, Johnson K. Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial. Clin. Cardiol. 24(11 Suppl.), V14-V16 (2001).
14. Thombs BD, Bass EB, Ford DE et al. Prevalence of depression in survivors of acute myocardial infarction. J. Gen. Intern. Med. 21(1), 30-38 (2006).
15. Lichtman JH, Bigger JT Jr, Blumenthal JA et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 118(17), 1768-1775 (2008).
16. Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom. Med. 67(3), 398-406 (2005).
17. Beitelshees AL, Gong Y, Wang D et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril Study (INVEST). Pharmacogenet. Genomics 17(9), 719-729 (2007).
18. Brunner M, Cooper-DeHoff RM, Gong Y et al. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am. J. Cardiol. 99(11), 1549-1554 (2007).
19. Gerhard T, Gong Y, Beitelshees AL et al. α-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVESTGENES). Am. Heart J. 156(2), 397-404 (2008).
20. Johnson AD, Gong Y, Wang D et al. Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin. Pharmacol. Ther. 85(1), 36-44 (2009).
21. Langaee TY, Gong Y, Yarandi HN et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin. Pharmacol. Ther. 81(3), 386-391 (2007).
22. Pacanowski MA, Gong Y, Cooper-Dehoff RM et al. β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther. 84(6), 715-721 (2008).
23. Pacanowski MA, Zineh I, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. Am. J. Hypertens. (2009).
24. Elliott WJ, Hewkin AC, Kupfer S, Cooper-DeHoff R, Pepine CJ. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. J. Clin. Hypertens. (Greenwich) 7(11), 654-663 (2005).
25. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290(21), 2805-2816 (2003). •• Primary findings of the INVEST clinical trial. Data includes baseline characteristics, blood pressure (BP) and drug treatment data and primary outcomes.
26. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients - findings from the International Verapamil SR/Trandolapril Study (INVEST). Am. Heart J. 151(5), 1072-1079 (2006). •• INVEST findings in the Hispanic cohort of patients enrolled in INVEST. INVEST has the largest cohort of Hispanic hypertensive coronary artery disease patients published to date.
27. Cooper-DeHoff RM, Handberg EM, Cohen J et al. Characteristics of contemporary patients with hypertension and coronary artery disease. Clin. Cardiol. 27(10), 571-576 (2004).
28. Zineh I, Cooper-Dehoff RM, Wessel TR et al. Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). Clin. Cardiol. 28(7), 321-328 (2005). • INVEST baseline characteristic and primary outcome data according to geographic regions of enrollment.
29. Bakris GL, Gaxiola E, Messerli FH et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 44(5), 637-642 (2004). •• INVEST findings in the cohort with diabetes at baseline.
30. Bangalore S, Messerli FH, Cohen JD et al. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am. Heart J. 156(2), 241-247 (2008).
31. Uretsky S, Messerli FH, Bangalore S et al. Obesity paradox in patients with hypertension and coronary artery disease. Am. J. Med. 120(10), 863-870 (2007).
32. Pepine CJ, Kowey PR, Kupfer S et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J. Am. Coll. Cardiol. 47(3), 547-551 (2006). •• Predictors of adverse outcomes in the INVEST clinical trial.
33. Cooper-Dehoff R, Cohen JD, Bakris GL et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am. J. Cardiol. 98(7), 890-894 (2006). •• Description of the cohort that developed diabetes during participation in INVEST and predictors of diabetes development.
34. Cooper-DeHoff RM, Gong Y, Marin J et al. Long-term Mortality Associated with New Onset Diabetes in Hypertensive CAD Patients Following Exposure to Antihypertensive medications: Findings from the INternational VErapamil SR/ Trandolapril Study. J. Am. Coll. Cardiol. Abstr. 0910-0917: A0224 (2009).
35. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur. Heart J. 29(10), 1327-1334 (2008).
36. Coca A, Messerli FH, Benetos A et al. Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST. Stroke 39(2), 343-348 (2008).
37. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann. Intern. Med. 144(12), 884-893 (2006). • Data from INVEST documenting a J-shaped curve associated with diastolic BP and adverse outcomes.
38. Mancia G, Messerli F, Bakris G et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 50(2), 299-305 (2007).
39. Gong Y, Handberg EM, Gerhard T et al. Systolic blood pressure and subjective well-being in patients with coronary artery disease. Clin. Cardiol. 26, 1-7 (2009).
40. Wright JT Jr, Probstfield JL, Cushman WC et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch. Intern. Med. 169(9), 832-842 (2009).
41. Garber AJ, Handelsman Y, Einhorn D et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr. Pract. 14(7), 933-946 (2008).
42. Aksnes TA, Kjeldsen SE, Rostrup M et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 50(3), 467-473 (2007).
43. Almgren T, Wilhelmsen L, Samuelsson O et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J. Hypertens. 25(6), 1311-1317 (2007).
44. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995-1003 (2002).
45. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
46. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
47. Jamerson K. ACCOMPLISH Ambulatory Blood Pressure Monitoring Substudy - data presented as Late Breaking Clinical Trial at the American Society of Hypertension, 2009 Scientific Sessions in San Francisco, California. (2009).
48. Opie LH. Controversies in cardiology. Lancet 367(9504), 13-14 (2006).
49. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462-1536 (2007).
50. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr. Pract. 12(2), 193-222 (2006).
51. Black HR, Elliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289(16), 2073-2082 (2003).
52. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).
53. Drug Topics. www.modernmedicine.com/ modernmedicine/data/articlestandard/ drugtopics/192009/597084/article.pdf (Accessed 11 June 2009)